(Developmental Research Program) The goal of the Developmental Research Program (DRP) of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising studies in translational prostate cancer research. It is directed by Dr. Timothy C. Thompson and co-directed by Dr. Christopher J. Logothetis. As with our current SPORE, the DRP in this renewal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients. The Prostate Cancer SPORE Administrative Core has established a broad-based effort for solicitation of potential DRP projects. Letters of intent of no more than 2 pages for innovative translational research are invited from MD Anderson and outside institutions and SPORE and non-SPORE investigators, including participants in the SPORE Career Enhancement Program. These applications will be screened by the program Director and co-Director (who also serve as the SPORE Principal investigator and co-Principal Investigator) according to objective criteria. Investigators of selected applications will be asked to prepare a 5-page proposal modeled after a National Institutes of Health R01. As appropriate, the Administrative Core Directors and staff will assist investigators submitting proposals formulate translational specific aims and research plans, as many of these investigators will not have expertise in these areas. The process constitutes a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the Prostate Cancer SPORE Leaders (Principal Investigators, Project co-Leaders, Program Directors, and Core Directors). The projects will be funded for 1 year and will be renewable for an additional year on the basis of established criteria. Developmental Research projects will be evaluated ad hoc and annually by the program Director/co- Director, SPORE Leaders, Executive Committee, and combined Internal/External Advisory Boards. The DRP has established a mechanism for termination of projects that do not meet our criteria for continuation; however, it has not been necessary to utilize this mechanism in the DRP to date. Nine developmental projects were funded in the current Prostate Cancer SPORE. Investigators receiving DRP grants wrote 29 publications related to the research supported by their grants during 2009-2014 and were awarded 19 external peer-reviewed grants. Importantly, 2 DRP awardees are investigators for major projects in the Prostate Cancer SPORE renewal application: Drs. Sue-Hwa Lin (co-Leader, Project 2) and Padmanee Sharma (co-Leader, Project 1), highlighting the importance of the DRP in identifying projects and investigators with potential value for translational research.
(Developmental Research Program) The goal of the Developmental Research Program of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising pilot studies in translational prostate cancer research that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients.
|Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169|
|Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461|
|Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176|
|Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707|
|Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106|
|Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76|
|Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43|
|Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924|
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174|
|Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69|
Showing the most recent 10 out of 217 publications